Large-cap Health Care company Catalent has logged a -0.2% change today on a trading volume of 190,465. The average volume for the stock is 2,317,692.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. Based in Somerset, United States the company has 18,000 full time employees and a market cap of $7,001,764,352.
The company is now trading -20.03% away from its average analyst target price of $48.57 per share. The 14 analysts following the stock have set target prices ranging from $40.0 to $58.0, and on average give Catalent a rating of buy.
Over the last 12 months CTLT shares have declined by -18.0%, which represents a difference of -35.0% when compared to the S&P 500. The stock's 52 week high is $74.49 per share and its 52 week low is $31.45. With its net margins declining an average -26.1% over the last 6 years, Catalent declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 4,488,000 | 22,000 | 0 | -100.0 |
| 2022 | 4,802,000 | 499,000 | 10 | -33.33 |
| 2021 | 3,998,000 | 585,000 | 15 | 114.29 |
| 2020 | 3,094,000 | 221,000 | 7 | 40.0 |
| 2019 | 2,518,000 | 137,000 | 5 | 66.67 |
| 2018 | 2,463,400 | 83,600 | 3 |
